At Scienta Lab, we are harnessing the potential of artificial intelligence to seize the biggest challenges in immunology today.
With cutting edge datasets, breakthrough capabilities in machine learning and world-class scientific collaborations, we are building a library of groundbreaking predictive algorithms.
Our library caters to academics and life-science companies involved in immunology to identify patient subgroups, predict patient prognosis, and treatment response for auto-immune diseases.
Scienta Lab presented its proprietary model, able to identify non-responders to MTX and TNFi based on limited number of clinical and lab variables, at the 2021 French Rheumatology Congress.
Book a demo through our formThere are more than 80 different auto-immune diseases, affecting 3 to 5% of the population around the world. Type 1 diabetes, lupus, rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis are the most common of these conditions.
Despite significant advances in understanding and classifying auto-immune diseases in the past decades, the challenge of heterogeneity remains a considerable. Heterogeneity impact both the onset and progression, diagnosis and prognosis of these diseases.
A multitude of anonymized data about patients with auto-immune conditions are generated everyday, including demographic information, disease activity index, biological data, images, treatments amongst others.
With breakthrough advancements in artificial intelligence and machine learning techniques, the possibility of translating this abundance of information into clinically relevant patterns is slowly becoming a reality.
At Scienta Lab, we are training our algorithms to identify patients, predict diagnosis and risk scores, and classify patients within auto-immune disease subgroups.
We are doing this by translating chaos into insights; yielding the largest ecosystem of datasets, scientific partnerships and machine learning capacities known to date.
The similarity of data across auto-immune diseases allows us to target develop a disease-targeted aproach, yet scale our models across the whole therapeutic area of immunology.
“The models developed by Scienta Lab help us to gain deep insights on auto-immune diseases. It paves the way to a better disease management and more favorable therapeutic outcomes for patients.”
Pr. Xavier Mariette, Head of Rheumatology Service, CHU Bicêtre, Paris, France
“Working with Scienta Lab enables us to have access to a whole new field in epidemiology and will help take better care of patients in the near future.”
Dr. Samuel Bitoun, Rheumatology fellow, CHU Bicêtre, Paris, France
SFR Congress 2021
L’intelligence artificielle prédit la non-réponse aux anti-TNF dans la polyarthrite rhumatoïde : résultats sur les cohortes ESPOIR et ABIRA
View abstractSFR Congress 2021
Prédiction de la non-réponse au méthotrexate dans la polyarthrite rhumatoïde par l’intelligence artificielle : résultats des cohortes ESPOIR, Leiden et t-REACH
View abstractScienta Lab is a French startup based in Paris, co-founded by a team with complementary skills and experiences.